PLAINSBORO, N.J., May 12, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced the launch of SurgiMend MP, its latest offering in tissue-building solutions for complex abdominal hernia repair. SurgiMend MP is a strong, 2mm thick acellular collagen matrix featuring a highly macroporous design that facilitates fluid drainage. The product offers physicians a biologic, yet cost-effective alternative to resorbable synthetic mesh to support healing, tissue building, and prolonged reinforcement in abdominal hernia repair.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/24d233ad-f70b-4b5b-9880-c686e49bf26a
"The addition of SurgiMend MP to our portfolio of biologic soft tissue repair products for hernia repair, and plastic and reconstructive surgery, provides general, trauma, colorectal, and plastic and reconstructive surgeons with another innovative solution in their surgical tool set," said Bob Davis, corporate vice president and president, Orthopedics and Tissue Technologies. "We believe SurgiMend MP will significantly strengthen our ability to limit uncertainty for surgeons looking to meet the challenging hernia repair needs of their patients with complex abdominal wall conditions."
SurgiMend MP is intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue membranes. SurgiMend MP is specifically indicated for plastic and reconstructive surgery, muscle flap reinforcement, and hernia repair, including abdominal, inguinal, femoral, diaphragmatic, scrotal, umbilical, and incisional hernias. SurgiMend MP will be available in numerous sizes ranging from 10cm x 15cm up to 25cm x 40cm to meet the varying needs of surgeons and their patients.
Integra LifeSciences is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Company Investors: Nora Brennan 609 936 2488 Michael Beaulieu 609 750 2827 email@example.com Media: Laurene Isip 609 750 7984 firstname.lastname@example.org